Active Clinical Trials and Research Studies

Active

The CONNECT study will test whether an oral, experimental drug, AZD0530 (Saracatinib), will slow progression in mild-stage Alzheimer's disease (AD). Although the cause of AD is unknown, several lines of evidence suggest that a peptide known as beta-amyloid plays a central role.  Convergent evidence in recent years has yielded a refinement of the "amyloid hypothesis", suggesting that neurotoxicity of beta-amyloid oligomers leads to Alzheimer's disease.

 

Researchers are looking for people who:

-- are 55-85 years of age,

Active

What is the purpose of this research study?

The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of BAN2401, a drug that may have the potential to treat Alzheimer's disease (AD). In AD, there are abnormally-high levels of a protein, called amyloid beta, in the brain. We hope that BAN2401 can reduce the amount of amyloid.

 

Who is eligible?

We are looking for participants who:

-- have been diagnosed with Mild Cognitive Impairment (MCI) or mild Alzheimer's disease dementia

-- are between the age of 50 and 90

Active

Coming soon!

Active

The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of solaneuzumab, a drug that may have the potential to slow the onset of Alzheimer's disease (AD). In AD, there are abnormally high levels of a protein, called amyloid in the brain. We hope that solaneuzumab can reduce the amount of amyloid in the brain.

 

We are looking for participants who:

-- do not have memory problem

-- are between age 65 and 85

-- have a reliable caregiver or family member who knows them well

-- are in stable medical condition

Active

We're looking for adults with AD, FTD, MCI or cognitive complaints, ages 50-95!

 

The purpose of this research study is to look at brain connectivity in a variety of people with memory problems, including people with complaints about their memory and people diagnosed with a neurodegenerative disease, including Alzheimer’s disease (AD), fronto-temporal dementia (FTD), and mild cognitive impairment (MCI).

 

What to expect:

•     one 3-hour visit

Active

The purpose of this study is to determine the presence of the protein Tau in the brain in a variety of populations, ranging from healthy adults to those diagnosed with a neurodegenerative disease.

 

What to expect:

-- 8-month study

-- Memory testing

-- MRI scans

-- PET scans

-- Blood work

-- Optional:  Lumbar puncture

 

Active

What is DIAN?

DIAN stands for the Dominantly Inherited Alzheimer’s Network.  This international network has been established by the National Institute on Aging of the National Institutes of Health (US) to bring together researchers who study genetic forms of Alzheimer’s disease (AD). 

 

Active

We are seeking healthy volunteers and individuals with Mild Cognitive Impairment (MCI) or Mild Alzheimer's Disease (AD) who are interested in taking part in a clinical research study to find out if functional MRI images of the brain can be used to diagnose and monitor the course and treatment of MCI and AD. Subjects must have a study partner and be willing to come to six to eight clinic visits over the course of two to three years.

 

Active

We are seeking healthy adults, aged 18 or older, to participate in a research study. The goal of the study is to examine olfactory function (or the sense of smell) in healthy individuals and in preclinical and clinical subjects with Alzheimer's Disease, Dementia with Lewy Bodies, or Frontotemporal Dementias.

 

Syndicate content